Let me ask a question. Do you know what these are?

StockWireNews

Breakout Idea (CTXR) Is A Nasdaq Past Champ With 5 Must-Know Potential Catalysts (Key Bullish Technicals)

April 24th

Greetings Readers,

Let me ask a question. Do you know what these are?

  • 4/18 - 12%
  • 4/11 - 31%
  • 4/6 - 110%
  • 4/4 - 40% intraday
  • 3/24 - 23% intraday

If not, that's okay. Allow me to fill you in.

That's a list of 5 of my recent alerts over the past month that went on to pop-off for strong, short term, approximate runs.

All total, that's approximately 216% combined in roughly 4+ weeks.

So what's next? Glad you asked.

When this profile was brought to you most recently, it popped 20% (approx.) in the matter of weeks.

And before that? An approximate multiple dollar runner a couple years back.

In 2021, it ran from an open of $1.99 to a high of $4.56 in a few short months.

Overall, that approximate $2.00+ surge resulted in this breakout idea running approximately 129%.

And based on a significant analyst target reiterated in March providing over 500% potential upside, 10+ triggered technical indicators, and the potential for FDA approval on the horizon, this past champ could be set for a breakthrough year in 2023.

There is only one Nasdaq biopharma idea to have on your watch-list:

*Citius Pharmaceuticals, Inc. (CTXR)*

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies.

And right now, this profile has 5 potential catalysts to be fully aware of. They include:

No. 1 - Could Multiple Triggered Technicals Signal Something Big On The Horizon?

No. 2 - A $10 Analyst Target Paints The Possibility For An Exceptionally Bright Future

No. 3 - Halo-Lido Phase 2b Study Continues To Move Forward

No. 4 - Company Aims To Maximize Value Of I/ONTAK While Advancing Pipeline

No. 5 - Corporate Update Provides Glimpse Of How Big 2023 Could Be For CTXR

But more on those in a second...

Citius Pharmaceuticals, Inc. (CTXR) Could Be A BioPharma Powerhouse Hiding In Plain Sight

Citius Pharmaceuticals is what’s called a “late-stage biopharmaceutical" company, where a highly-experienced management team purchases rights to the most promising new therapies and then either brings them to market or licenses rights to bigger pharma companies like Pfizer or Johnson & Johnson.

It should go without saying that “late-stage” development is the most difficult, most expensive part of the process for any new kind of treatment. Because even after years of in-vest-ment, research and development, some 2 out of 5 drugs still fail to secure final FDA approval.

But with a “Dream Team” of top industry insiders, Citius is turning the odds in their favor—with two treatments now in Phase 3.

Citius Pharmaceuticals quietly acquired the rights to the experimental compound “E-7777,” a direct improvement to a previously FDA-approved medication that directly attacks infected cancer cells inside the human body.

And this new cancer-fighting remedy could be mere months away from its own approval. If and when it hits the market, this new treatment could provide a whole new proven alternative to the harsh side effects of chemotherapy or aggressive radiation treatment.

Directly targeting and attacking infected cells, E-7777 could transform the potential $12.57Bn future market for Non-Hodgkin’s Lymphoma treatment.

The best part of this whole story? This is just one of several potentially game-changing new therapies in the company’s pipeline…

image

(Source)

In addition to E-7777, it’s currently advancing three proprietary product candidates in total:

  • CITI-002 (Halo-Lido), a topical formulation of halobetasol, a corticosteroid, and lidocaine to provide anti-inflammatory and anesthetic symptomatic relief to hemorrhoids victims. It is currently gearing up for a Phase IIb trial.
  • CITI-101 (Mino-Wrap), a liquefying gel-based wrap containing minocycline and rifampin designed to provide inflammatory tissue protection and prevent infection and biofilm formation in tissue expanders and breast implants post-mastectomy. In December 2020, Citius received a written response and guidance from the USFDA for Mino-Wrap development. Citius expects to file for an IND by the end of this year.
  • Mino-Lok, an antibiotic lock solution developed as adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). If approved, Citius believes that Mino-Lok could enter a $1.5Bn worth market and prove to be a blockbuster without any immediate competition.

-----

And right now, CTXR has 5 potential catalysts to soak in this second. Following along...

No. 1 CTXR Potential Catalyst - Could Multiple Triggered Technicals Signal Something Big On The Horizon?

I'm telling you right now... Don't discount CTXR's bullish technical indicators.

At close on Friday, CTXR was displaying several triggered technical indicators across the short, medium term, and long term.

Barchart was reporting these as triggered:

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 50 Day MACD Oscillator
  • 20 - 100 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 100 Day MACD Oscillator
  • 50 - 150 Day MACD Oscillator
  • 50-200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

The website also shares its all-important "Trend Seeker" composite indicator is triggered.

Watch these technicals closely this week.

-----

No. 2 CTXR Potential Catalyst - A $10 Analyst Target Paints The Possibility For An Exceptionally Bright Future

Back in March, Jason Kolbert, an analyst with Dawson James Securities, reiterated a $10.00 target on CTXR.

That provides CTXR with a mind-blowing potential upside over 500% from Friday's close.

Here's some key highlights from the report:

Mino-Lok is approaching the finish line: Management did not update the number of catheter failure events but previously stated that they “expected to achieve 92 catheter failure events with 144 patients by the end of 2022”, and “We have now exceeded our targeted enrollment and have achieved 72 of the required catheter failure events” , “we anticipate that the 92-event threshold required to complete the trial is achievable in the coming months." We will look for an update on the trial enrollment soon.

ONTAK BLA Under Review. The U.S. Food and Drug Administration (FDA) is currently reviewing a biologics license application (BLA) for I/ONTAK and has set a targeted decision date (PDUFA) of July 28, 2023. As we have stated in the past, management is now planning to spin-out IONTAK into a new company and raise capital to support the product’s commercialization. Recall that Citius paid $40M upfront and has an obligation for $40M in milestones, and we assume a 10% royalty. Given the opportunity, combined with what we view as a low-risk therapeutic, we believe management can realize a significant return on its in-vest-ment.

Valuation. Our valuation is based on our therapeutic models and associated assumptions projected to 2028. The lead product, Mini-Lok, is now in a Phase 3 trial, as is E7777. We use a 30% risk rate in our free cash flow to the Firm (FCFF), our discounted EPS (dEPS), and sum-of-the-parts (SOP) models on top of a 15% risk rate in our therapeutic models for both products. We equal weight and average these metrics and then round to the nearest whole number to derive our $10.00 price target.

-----

No. 3 CTXR Potential Catalyst - Halo-Lido Phase 2b Study Continues To Move Forward

Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Topline Results anticipated by the end of Q2 2023CRANFORD, N.J., April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA).

Approximately 300 adults with a clinical diagnosis of symptomatic hemorrhoids were enrolled in the Halo-Lido Phase 2b study (NCT05348200), a multi-center, randomized, dose-ranging, double-blind, parallel group comparison clinical trial. The primary outcome of the study is the change in hemorrhoidal symptoms as reported by the patients following treatment. Efficacy and safety data are recorded by patients utilizing a proprietary mobile-enabled Patient Reported Outcome (ePRO) instrument. The results of the study are anticipated by the end of the second quarter of 2023 and are expected to provide the foundation for development of the Phase 3 study.

"The completion of the Phase 2b enrollment is an important milestone for Citius. We are hopeful that analysis of the study data will support further evaluation of the potential of CITI-002 to provide relief for hemorrhoid patients. We congratulate our clinical management team, our CRO staff and the principal investigators who helped us achieve this milestone in a timely fashion. The study was fully enrolled within one year from initiation. We continue to believe that the global market for a prescription topical treatment for hemorrhoids is large and underserved. Contingent on the trial data, we expect to continue to advance this program to maximize its value," stated Leonard Mazur, Executive Chairman of Citius.

Read the full article here.

-----

No. 4 CTXR Potential Catalyst - Company Aims To Maximize Value Of I/ONTAK While Advancing Pipeline

Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company

CRANFORD, N.J., March 30, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as fi-nan-cial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. The U.S. Food and Drug Administration (FDA) is currently reviewing a biologics license application (BLA) for I/ONTAK and has set a targeted decision date (PDUFA) of July 28, 2023.

"Citius is committed to maximizing the value of I/ONTAK and advancing our pipeline. Maxim Group has a strong track record of executing strategic and fi-nan-cial transactions in the life science sector, and we look forward to working closely with them to optimize the structure and timing of contemplated I/ONTAK transactions," stated Leonard Mazur, Chairman and CEO of Citius.

Any transactions would be subject to the satisfaction of customary conditions, including final approval from the Citius Board of Directors, regulatory approvals, and SEC filings. Upon closing of the transactions, Citius would continue to trade on the Nasdaq exchange under its current ticker CTXR.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. There can be no assurance regarding the ultimate timing of proposed transactions or that the transactions will be completed at all.

Read the full article here.

-----

No. 5 CTXR Potential Catalyst - Corporate Update Provides Glimpse Of How Big 2023 Could Be For CTXR

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Fi-nan-cial Results and Provides Business Update

$41.7Mn in cash and cash equivalents as of September 30, 2022; extends runway through December 2023

Mino-Lok® Phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review

I/ONTAK BLA accepted for filing by the FDA; updated PDUFA target action date is July 28, 2023

Halo-Lido Phase 2b trial progressed; data readout expected 2H 2023

Multiple value-driving catalysts anticipated in 2023, including a potential drug approval and two trial completions

CRANFORD, N.J., Dec. 22, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and fi-nan-cial results for the fiscal full year ended September 30, 2022.

Fiscal Full Year 2022 Business Highlights and Subsequent Developments

  • Completed Pivotal Phase 3 trial of I/ONTAK (E7777) and submitted biologics license application (BLA) to the U.S. Food and Drug Administration (FDA);
  • FDA confirmed Prescription Drug User Fee Act (PDUFA) target action date of July 28, 2023;
  • Advanced Mino-Lok® Phase 3 trial;
  • Initiated Phase 2b trial of Halo-Lido for the treatment of hemorrhoids in April 2022; patient enrollment ongoing with data readout expected 2H 2023;
  • Initiated clinical collaboration with the University of Pittsburgh to evaluate regulatory T-cell (T-reg) depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid cancer tumors in a Phase 1 investigator-initiated trial, with first patient enrolled in November 2022; and,
  • Approved for $3.6Mn in non-dilutive capital through the New Jersey Economic Development Program to support ongoing research and development efforts.

...

Read the full article here.

-----

CTXR Recap - 5 Key Potential Catalysts For This Nasdaq Past Champ

No. 1 - Could Multiple Triggered Technicals Signal Something Big On The Horizon?

No. 2 - A $10 Analyst Target Paints The Possibility For An Exceptionally Bright Future

No. 3 - Halo-Lido Phase 2b Study Continues To Move Forward

No. 4 - Company Aims To Maximize Value Of I/ONTAK While Advancing Pipeline

No. 5 - Corporate Update Provides Glimpse Of How Big 2023 Could Be For CTXR

-----

Coverage is officially reinitiated on CTXR. When you have time later, do this:

image

Get CTXR on your radar now.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews was hired for a period beginning on 7/26/19 and ending on 7/29/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 9/3/19 and ending on 9/4/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 12/18/19 and ending on 12/19/19 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNesWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 2/4/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 3/11/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a period beginning on 4/2/20 and ending on 4/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-five thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 4/28/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a one day period on 5/13/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 6/2/20 and ending on 6/3/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 7/7/20 and ending on 7/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 8/4/20 and ending on 8/5/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid ten thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Venado Media LLC, StockWireNews has been hired for a two day period beginning on 9/17/20 and ending on 9/18/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a one day period beginning on 10/6/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for an additional one day period beginning on 10/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid two thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for an additional one day period beginning on 12/8/20 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid sixty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 2/16/21 and ending on 2/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 4/29/21 and ending on 4/30/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 5/18/21 and ending on 5/19/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/8/21 and ending on 6/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 6/16/21 and ending on 6/17/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 7/8/21 and ending on 7/9/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/7/21 and ending on 9/8/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid sixty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 12/6/21 and ending on 12/7/21 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a one day period on 5/6/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (CTXR). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/22/22 and ending on 9/23/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. SWN Media LLC was paid ninety thousand USD via bank wire transfer. We own zero shares of (CTXR). This ninety thousand USD in compensation was applied towards profiles on multiple companies. Pursuant to an agreement between SWN Media LLC and TD Media, LLC, StockWireNews has been hired for a period beginning on 1/18/23 and ending on 1/19/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. SWN Media LLC was paid five thousand USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between SWN Media LLC and TD Media, LLC, StockWireNews has been hired for a period beginning on 1/22/23 and ending on 1/23/22 to publicly disseminate information about (CTXR) via Website, Email and SMS. SWN Media LLC was paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). Pursuant to an agreement between SWN Media LLC and TD Media, LLC, StockWireNews has been hired for a period beginning on 4/23/23 and ending on 4/25/23 to publicly disseminate information about (CTXR) via Website, Email and SMS. SWN Media LLC was paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (CTXR). To date we have now been compensated a total of seven hundred and fifty-five thousand five hundred USD via bank wire transfer to disseminate information about (CTXR). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Amalfi Media LLC, TD Media LLC has been hired for a period beginning on 04/23/2023 and ending on 04/25/2023 to publicly disseminate information about (CTXR:US) via digital communications. We have been paid an additional eighty five thousand dollars USD. To date we have been paid one million one hundred thirty one thousand five hundred fifty dollars USD to disseminate information about (CTXR:US) via digital communications. We own zero shares of (CTXR:US). lifewatermedia.com/ctxr-disclosure-47/